A股異動丨中期業績不及預期 恆瑞醫藥(600276.SH)大跌9%
格隆匯8月20日丨恆瑞醫藥(600276.SH)跳空低開,現大跌9%,報49元創近2年新低價,總市值3128億元。恆瑞醫藥上半年實現淨利潤26.68億元,同比增長0.21%增速創18年新低。香港中央結算持股由12.26%降至11.97%,奧本海默基金退出前十大股東。中金報吿表示,因仿製藥受集採影響持續承壓及核心產品銷售走低,恆瑞醫藥上半年業績不及預期,下調公司盈利預測及目標價,維持跑贏行業評級,下調目標價33.3%至80元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.